Viewing nowPregalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea United Pharm, Co., Ltd.

MFDS item code 201109238 · Approved 2011.10.27 · Insurance code 642802410
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This medication is effective for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for patients with epilepsy to help control partial seizures. It is utilized for alleviating pain in fibromyalgia patients. In other words, it is used for peripheral and central neuralgia, adjunctive treatment for epilepsy, and improvement of fibromyalgia.
This medicine is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Because this medicine is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg/day. The initial dose is 75mg twice daily (150mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg/day). For patients who do not experience sufficient benefit at a dose of 300mg/day, the dose may be increased within 1 week to 225mg twice daily (450mg/day). Clinical studies have also been conducted at a dose of 600mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is eliminated primarily by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. * : For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours) In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin, starting dose 150 (mg/day), maximum dose 600 (mg/day), dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin, starting dose 75 (mg/day), maximum dose 300 (mg/day), dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin, starting dose 25-50 (mg/day), maximum dose 150 (mg/day), dosing regimen QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin, starting dose 25 (mg/day), maximum dose 75 (mg/day), dosing regimen QD Supplemental dose after hemodialysis: starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified under dosing regimen. b : Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12∼17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior; if symptoms of depression, mood changes, or abnormal behavior occur during treatment, immediately inform healthcare professionals. Do not take this medication if you have an allergy to any of its components. Patients with specific genetic issues such as lactose intolerance should also refrain from using this drug. Diabetic patients may experience weight gain due to this medication, which may require an adjustment in their blood glucose control drugs. In case of severe allergic reactions such as angioedema, discontinue the medication immediately and consult with healthcare professionals. Elderly patients may experience increased dizziness or drowsiness while taking this medication; hence, they should be cautious and avoid hazardous activities until they are accustomed to the medication. Some patients may experience blurred vision or changes in vision; it is important to notify healthcare professionals if these symptoms arise. If this medication is suddenly discontinued, withdrawal symptoms such as insomnia, headaches, and anxiety may occur; therefore, it should be tapered off gradually under the guidance of a healthcare professional. Patients with a history of drug abuse may have an increased risk of misuse with this medication; extra caution should be taken and they should be closely monitored for signs of misuse or dependence. Patients with impaired kidney function may require dose adjustments of this medication. Patients with severe heart diseases should exercise caution while using this medication, especially those with congestive heart failure who should use it with caution. Concurrent use of this medication with opioid analgesics may increase central nervous system depression; therefore, caution is advised. Patients with respiratory diseases, kidney impairment, elderly individuals, etc. are at risk for severe respiratory depression, and should discuss with healthcare professionals before using this medication. In early pregnancy, the use of this medication may affect the fetus, so it is advisable for pregnant women to avoid it, and women of childbearing age should use effective contraception. Breastfeeding women should be aware that this medication can be transmitted through breast milk, and should consult healthcare professionals about stopping breastfeeding or the medication. When engaging in hazardous activities such as driving or operating machinery, caution should be taken as dizziness or drowsiness may occur after taking this medication. If severe skin reactions such as rashes, blisters, or intense itching occur while using this medication, it should be discontinued immediately and the healthcare professional should be informed. In the case of overdose, symptoms may include confusion, drowsiness, and depression, and appropriate treatment such as hemodialysis may be required.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal ideation, pain, seizures, excessive sweating, misuse, abuse, dependency, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual arousal disorder, agitation, mood disturbances, emotional lowering, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, abnormal motor coordination, balance disorder, amnesia, attention deficit, memory impairment, tremors, speech disorder, sensory abnormalities, sensory reduction, calming, drowsiness syndrome, cognitive disorder, nystagmus, language difficulties, asthenopia, diminished reflexes, movement abnormalities, psychomotor agitation, orthostatic dizziness, heightened perception, burning sensation, action tremors, syncope, confusion, decreased motor activity, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field loss, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, vibrations, changes in the depth perception of the visual field, strabismus, visual brightness, vertigo, auditory hyperesthesia, degree 1 AV block, tachycardia, bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distention, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory reduction, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, swelling, gait abnormalities, falls, feeling of intoxication, abnormal sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confused state, agitation, restlessness, exacerbation of convulsions, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to store the medication at room temperature, which should not be too hot or too cold, ideally between 15 to 30 degrees Celsius.
A reddish-brown, hard capsule containing a white powder that is white or light yellow in color
Domestic Use: 30 capsules/bottle Export Use: 28 capsules (7 capsules/PTP×4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Korea United Pharm, Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.